A5085156317- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Cancer therapeutics and mechanisms
- Cancer Treatment and Pharmacology
- Neuroendocrine Tumor Research Advances
- HER2/EGFR in Cancer Research
- Chronic Lymphocytic Leukemia Research
- Advanced Breast Cancer Therapies
- Acute Myeloid Leukemia Research
- Peptidase Inhibition and Analysis
- Colorectal Cancer Treatments and Studies
- Monoclonal and Polyclonal Antibodies Research
- Lung Cancer Diagnosis and Treatment
- Radiopharmaceutical Chemistry and Applications
- Pancreatic and Hepatic Oncology Research
- Bladder and Urothelial Cancer Treatments
- Gastric Cancer Management and Outcomes
- Prostate Cancer Treatment and Research
- Multiple and Secondary Primary Cancers
- Lymphoma Diagnosis and Treatment
- Protein Degradation and Inhibitors
- Multiple Myeloma Research and Treatments
- Renal cell carcinoma treatment
- Cancer Genomics and Diagnostics
Reata Pharmaceuticals (United States)
2023-2024
Virginia Oncology Associates
2014-2023
MedStar Washington Hospital Center
2021
The US Oncology Network
2010-2020
Eastern Virginia Medical School
2015
Comprehensive Cancer Centers of Nevada
2010-2012
Arizona Oncology
2007-2012
McKesson (United States)
2012
IQVIA (United States)
2012
Texas Oncology
2004-2012
Purpose This phase II study evaluated the safety and efficacy of single-agent amrubicin versus topotecan in patients with small-cell lung cancer (SCLC) sensitive to first-line platinum-based chemotherapy. Patients Methods were randomly assigned 2:1 (40 mg/m 2 /d a 5-minute intravenous [IV] infusion, days 1 through 3, every 21 days) or (1.5 30-minute IV 5, days). The primary end point was overall response rate (ORR) for amrubicin. Secondary points included time progression, median...
Overexpression of C-X-C motif receptor 4 (CXCR4) is implicated in tumor progression. LY2510924 a peptide antagonist, which blocks stromal cell-derived factor-1 (SDF1) from CXCR4 binding.This phase I study included two parts: 3+3 dose escalation (part A) and confirmation B). was administered as daily subcutaneous injection on 28-day cycle. The primary objective to determine the recommended II dose. Secondary objectives safety, pharmacokinetics, efficacy, pharmacodynamic response, including...
This phase I study (RAD1901-005; NCT02338349) evaluated elacestrant, an investigational oral selective estrogen receptor degrader (SERD), in heavily pretreated women with receptor-positive, human epidermal growth factor 2-negative metastatic breast cancer, including those gene alpha (
Atezolizumab [anti-programmed death-ligand 1 (anti-PD-L1)] is well tolerated and efficacious in multiple cancers, but has not been previously evaluated metastatic castration-resistant prostate cancer (mCRPC). This study examined the safety, efficacy, biomarkers of atezolizumab monotherapy for mCRPC.This phase Ia, open-label, dose-escalation dose-expansion (PCD4989g) enrolled patients with mCRPC who had progressed on sipuleucel-T or enzalutamide. was given intravenously every 3 weeks until...
Amrubicin is a synthetic anthracycline with potent topoisomerase II inhibition. This phase study was conducted to confirm safety and activity of amrubicin in the treatment refractory small-cell lung cancer (SCLC).Patients SCLC (either progressive disease as best response or progression within 90 days first-line therapy) received (40 mg/m(2)/d for 3 every 21 days). The primary end point overall rate (ORR); secondary points included progression-free survival (PFS), (OS), change left...
8008 Background: Human lung cancer expresses high levels of PD-L1, which may inhibit anti-cancer immune responses. MPDL3280A, a human monoclonal Ab containing an engineered Fc-domain designed to optimize efficacy and safety, targets blocking PD-L1 from binding its receptors, including PD-1 B7.1. Methods: Pts with squamous or nonsquamous NSCLC received MPDL3280A IV q3w at doses between 1-20 mg/kg in Ph I expansion study. were treated for up 1 y. Objective response rate (ORR) was assessed by...
CC-486 (oral azacitidine) is an epigenetic modifier in clinical development for treatment of hematological cancers. This study extended dosing included patients with myelodysplastic syndromes (MDSs), chronic myelomonocytic leukemia (CMML), or acute myeloid (AML). After a pharmacokinetic assessment period, 31 (MDS n = 18, CMML 4, and AML 9) entered phase which they received 300 mg once-daily 21 days repeated 28-day cycles. Median age was 71 years (range: 53-93); 42% were aged ≥75 years. A...
470 Background: Multiple approved immunotherapy (IO)-based combination regimens have demonstrated efficacy as first-line (1L) tx for mRCC, but also shown notable toxicity. These factors may lead to variations in how are used RW community oncology care. No direct, prospective comparison exists FDA-approved IO-IO or IO + tyrosine kinase inhibitor (IO-TKI) mRCC. This study assessed 1L TKI dosing patterns and outcomes of pts with mRCC a large network US practices. Methods: A retrospective,...
480 Background: In the United States, adjuvant pembrolizumab was approved on November 17, 2021, for patients with RCC intermediate-high (T2N0M0-G4, T3N0M0, any grade) or high risk (T4, grade; N+, T, and M1NED patients) of recurrence following nephrectomy. This study aims to assess adoption in routine practice demographic clinical characteristics post nephrectomy who received this therapy. Methods: retrospective included adult non-metastatic localized underwent between December 31, 2022, were...
Avelumab first-line maintenance (1LM) is approved for patients with locally advanced or metastatic urothelial carcinoma (la/mUC) who do not have disease progression after platinum-based chemotherapy (PBC). This retrospective study describes real-world treatment patterns and clinical outcomes in la/mUC initiated (1L) systemic treatments, including avelumab 1LM, within iKnowMed, the US community oncology electronic health records database, between 1 December 2019 30 November 2023 followed...
Abstract Tissue factor is a lipoprotein, expressed on the surface of cells, which binds coagulation Factor VII or VIIa, leading to activation Factors X and IX with subsequent fibrin generation. Cellular tissue activity important in pathophysiologic processes such as inflammation disseminated intravascular coagulation. In this study, long-chain base sphingosine inhibited initiated by lipopolysaccharide-stimulated intact human monocytes. Sphingosine (5-100 microM) also profoundly...
Abstract Background. Esophageal and gastric cancers often present at an advanced stage. Systemic chemotherapy is the mainstay of treatment, but survival with current regimens remains poor. We evaluated safety, tolerability, efficacy combination capecitabine, oxaliplatin, bevacizumab in treatment metastatic esophagogastric adenocarcinomas. Methods. Thirty-seven patients or unresectable gastric/gastroesophageal junction tumors were enrolled treated capecitabine 850 mg/m2 BID on days 1–14,...
Transforming growth factor β (TGF-β) plays an important role in cancer. Monoclonal antibodies (mAb) designed to specifically block the TGF-β ligands, are expected inhibit tumor progression patients with metastatic TβM1 is a humanized mAb optimized for neutralizing activity against TGF-β1. The objective of this clinical trial was assess safety and tolerability In phase I, uncontrolled, non‑randomized, dose-escalation study, 18 eligible adult who had measurable disease per RECIST performance...
651 Background: MM-111 (111) inhibits ligand activated HER3 signaling in HER2+ tumors. This study evaluated the safety of 111 combined with standard care (SOC) HER2-targeting regimens (Rx): capecitabine (X) + cisplatin (C) trastuzumab (T) (Arm 1); lapatinib (L) +/- 2); paclitaxel (P) 3); 4); docetaxel (D) 5). Methods: was a multi-arm Phase 1, dose escalation combination SOC to evaluate safety, pharmacokinetics (PK), and anti-tumor activity. Patients were required have documented advanced...
This phase Ib study evaluated the safety, tolerability, pharmacokinetics, and preliminary efficacy of oral AKT inhibitor ipatasertib chemotherapy or hormonal therapy in patients with advanced metastatic solid tumors to determine combined dose-limiting toxicities (DLTs), maximum tolerated dose, recommended II doses schedules.The clinical comprised four combination treatment arms: arm A (with docetaxel), B [with mFOLFOX6 (modified leucovorin, 5-fluorouracil, oxaliplatin)], C paclitaxel), D...